Clinical Trial Update: Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating isatuximab with bendamustine for systemic light-chain (AL) amyloidosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Light-chain Amyloidosis

Drugs mentioned

• SARCLISA (isatuximab)
• Treanda (Bendamustine)

Snippet

Sponsor: Tufts Medical Center | Conditions: Amyloidosis, Light Chain (AL) Amyloidosis | Phase 2 | Status: WITHDRAWN